

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE AND THE STRATEGIC COMMITTEE

Reference is made to the announcement (the “**Previous Announcement**”) and circular (the “**Circular**”), both dated 29 November 2024 of Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) in relation to, among other things, the proposed election of each of Mr. Li Zhongxian (“**Mr. Li**”) and Ms. Lu Kun (“**Ms. Lu**”) as an Independent Non-executive Director of the Company.

Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

I. ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS

(1) Election of Mr. Li

The Board is pleased to announce that resolution number 3(i) regarding the election of Mr. Li as an Independent Non-executive Director was approved at the EGM held on 20 December 2024. The election of Mr. Li as an Independent Non-executive Director has become effective on the date of the EGM, being 20 December 2024. Poll results of the EGM are set out in the poll results announcement of the Company dated 20 December 2024.

The biographical details and other relevant information regarding Mr. Li are set out in the Previous Announcement and the Circular. As at the date of this announcement, there has been no change to such information save as otherwise disclosed in this announcement.

The Company will enter into a service contract with Mr. Li in relation to his election as an Independent Non-executive Director for a term commencing from the date of approval of his election at the EGM, being 20 December 2024, and expiring on the conclusion of the fourth session of the Board. This term of office is determinable by either party serving on the other not less than three months' written notice, and subject to retirement by rotation and re-appointment in accordance with the Articles of Association and the Hong Kong Listing Rules. Under the terms of the service contract, the director's fee payable to Mr. Li will be RMB200,000 per annum, which was determined with reference to his duties and responsibilities in the Company and prevailing market conditions, and will be subject to review by the Board and the Remuneration and Appraisal Committee from time to time. Mr. Li has not entered into nor proposed to enter into any service contracts, which fall within the meaning of Rule 13.68 of the Hong Kong Listing Rules requiring the prior approval of Shareholders at general meetings, with the Company.

Mr. Li has confirmed that he has met the independence criteria set out in Rule 3.13 of the Hong Kong Listing Rules.

Save as disclosed above, there are no other matters concerning Mr. Li's election as an Independent Non-executive Director that need to be brought to the attention of the Shareholders nor any information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Hong Kong Listing Rules.

(2) Election of Ms. Lu

The Board is pleased to announce that resolution number 3(ii) regarding the election of Ms. Lu as an Independent Non-executive Director was approved at the EGM held on 20 December 2024. The election of Ms. Lu as an Independent Non-executive Director has become effective on the date of the EGM, being 20 December 2024. Poll results of the EGM are set out in the poll results announcement of the Company dated 20 December 2024.

The biographical details and other relevant information regarding Ms. Lu are set out in the Previous Announcement and the Circular. As at the date of this announcement, there has been no change to such information save as otherwise disclosed in this announcement.

The Company will enter into a service contract with Ms. Lu in relation to her election as an Independent Non-executive Director for a term commencing from the date of approval of her election at the EGM, being 20 December 2024, and expiring on the conclusion of the fourth session of the Board. This term of office is determinable by either party serving on the other not less than three months' written notice, and subject to retirement by rotation and re-appointment in accordance with the Articles of Association and the Hong Kong Listing Rules. Under the terms of the service contract, the director's fee payable to Ms. Lu will be RMB200,000 per annum, which was determined with reference to her duties and responsibilities in the Company and prevailing market conditions, and will be subject to review by the Board and the Remuneration and Appraisal Committee from time to time. Ms. Lu has not entered into nor proposed to enter into any service contracts, which fall within the meaning of Rule 13.68 of the Hong Kong Listing Rules requiring the prior approval of Shareholders at general meetings, with the Company.

Save as disclosed above, there are no other matters concerning Ms. Lu's election as an Independent Non-executive Director that need to be brought to the attention of the Shareholders nor any information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Hong Kong Listing Rules.

Ms. Lu has confirmed that she has met the independence criteria set out in Rule 3.13 of the Hong Kong Listing Rules.

The Board would like to take this opportunity to extend a warm welcome to Mr. Li and Ms. Lu for joining the Board.

II. CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE AND THE STRATEGIC COMMITTEE

The Board is pleased to announce that, following the resolution regarding the election of Mr. Li as an Independent Non-executive Director being passed at the EGM, with effect from 20 December 2024, Mr. Li is elected as a member of the audit committee of the Company (the "**Audit Committee**"), and Dr. Wang Gang and Dr. Feng Xiaoyuan are elected as a member of the strategic committee of the Company (the "**Strategic Committee**"). The term shall commence from the date of Board meeting, being 20 December 2024, until the end of term for the fourth session of the Board. Following the above changes, the composition of the Audit Committee and the Strategic Committee will be as follows:

- (i) the Audit Committee comprises two Independent Non-executive Directors, namely Mr. Zhang Chun (chairman of the Audit Committee) and Mr. Li, and one non-executive Director, namely Mr. Tang Yi; and
- (ii) the Strategic Committee comprises three executive Directors, namely Mr. Xiong Jun (chairman of the Strategic Committee), Dr. Zou Jianjun and Dr. Wang Gang, and two Independent Non-executive Directors namely Mr. Zhang Chun and Dr. Feng Xiaoyuan.

The Board would like to take this opportunity to extend a warm welcome to Mr. Li, Dr. Wang Gang and Dr. Feng Xiaoyuan for taking up new positions.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 20 December 2024

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; Mr. Tang Yi as non-executive Director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Dr. Yang Yue, Mr. Li Zhongxian and Ms. Lu Kun as Independent Non-executive Directors.

* *For identification purpose only*